Back to search results

Tai Chi for Chemotherapy-Induced Peripheral Neuropathy (CIPN)

This study is testing if a 12-week online Tai Chi program is practical and well-received by cancer survivors who have chemotherapy-induced peripheral neuropathy (CIPN). CIPN is nerve damage caused by certain chemotherapy drugs like platinum agents or taxanes, leading to symptoms like numbness or pain. You might be able to join if you are 18 or older, are a cancer survivor with no active cancer, and completed neurotoxic chemotherapy at least three months ago with a CIPN diagnosis. The main goal is to see how many people enroll, complete assessments, and finish the Tai Chi sessions. About 21 people are expected to participate.

Study design
This is a pilot study that will randomly assign participants to either a Tai Chi group or a waitlist group. About 21 people are expected to participate.
What's involved
You would participate in a 12-week virtual Tai Chi program. This includes screening, questionnaires, and sensory and functional testing.
Compensation
Not stated in the trial record.
Follow-up
Assessments will be completed for up to 12 weeks, and the enrollment rate will be measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06807294

Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)

Recruiting
NAAges 18+InterventionalSupportive care
Dana-Farber Cancer Institute
~21 participants
Updated 2026-01-29 on ClinicalTrials.gov
What's tested:Tai Chi Program

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Enrollment Rate for the Tai Chi Program
Measured over 6 months
+3 more outcomes measured

Conditions

Chemotherapy Induced Peripheral Neuropathy (CIPN)
Peripheral Neuropathy Due to Chemotherapy
Peripheral Neuropathies
Neuropathy

Explore related trials

Chemotherapy-Induced Peripheral Neuropathy

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Ting Bao, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Ting Bao, MD
[email protected]
857-215-2844
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years old and older
Cancer survivors with no evidence of disease (cancer);
Completed neurotoxic chemotherapy, i.e., platinum agents, taxanes, vinca alkaloids, and bortezomib, at least three months before enrollment;
A CIPN diagnosis based on symptom history, loss of deep tendon reflexes, or presence of symmetrical stocking-glove pain, numbness, or paresthesia;
Answers "yes" to the following question: "Do you feel as though your balance is affected from experiencing CIPN?" or "Are you afraid of falling as a result of your CIPN?";
On a stable regimen (no change in past three months) if taking anti-neuropathy or other pain medications;
Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤ 2
Willing to adhere to all study-related procedures, including randomization to the Tai Chi or waitlist group, 2 in-person visits to Dana-Farber Cancer Institute (DFCI) (one within 2 weeks of enrollment and one at week 12);
Willing to adhere to requirement that no new pain medication be taken throughout the study period; and
Individuals receiving endocrine therapy or targeted/antibody therapy, such as trastuzumab, pertuzumab, or immunotherapy, will be eligible to participate.

What this trial measures

  • Enrollment Rate for the Tai Chi Program6 months

    The intervention is considered feasible if 21 participants are enrolled within the first 6 months of the study period.

  • Assessment Completion Rate12 weeks

    The intervention is considered feasible if 75% of all evaluable participants, 16 out of 21, complete the biobehavioral assessments during the intervention period.

  • Session Completion Rate12 weeks

    The intervention is considered feasible if 62% of participants in the intervention arm, 9 out of 14, attend at least 80% or 20 of the 24 online sessions.

  • Acceptability of Intervention Measure (AIM) Score12 weeks

    Assessed by the Acceptability of the Intervention Measure (AIM), a 4-item measure rated on a 5-point Likert scale with answers ranging from "Completely disagree" to "Completely agree." A total scores range is 4 to 20 with a higher score indicating greater acceptability.